AUA 2020 - American Urological Association Annual Meeting (Virtual Meeting)
May 15 - May 18, 2020 | Washington, DCUS
LARVOL is not affiliated with American Urological Association Annual Meeting (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 69 abstracts linked to Trials
[VIRTUAL] HERO Phase 3 Trial: Results Comparing Relugolix, an oral GnRH receptor antagonist, vs leuprolide acetate for advanced prostate cancer
[VIRTUAL] Pembrolizumab Plus Enzalutamide in Abiraterone-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer: Updated Results From KEYNOTE-365 Cohort C
[VIRTUAL] Impact of baseline disease volume and prior docetaxel therapy on prostate-specific antigen-related outcomes in patients with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus androgen deprivation therapy
[VIRTUAL] Effect of cabazitaxel vs abiraterone or enzalutamide on patient-reported outcomes in metastatic castration-resistant prostate cancer: A pre-planned EQ-5D-5L analysis of the CARD study
[VIRTUAL] Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in TITAN: Prognostic Importance of Prostate-Specific Antigen Responses
[VIRTUAL] Association of an immune-gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC)
[VIRTUAL] Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial
[VIRTUAL] Can TURBT be avoided? Primary chemoablation with a reverse thermal gel containing mitomycin (UGN-102) in patients with low grade intermediate risk non-muscle invasive bladder cancer
[VIRTUAL] Methylation of SRD5A2 promoter predicts a better outcome for patients undergoing androgen deprivation therapy in patients with Castration-Resistant Prostate Cancer
[VIRTUAL] No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study
[VIRTUAL] Adjuvant Intraarterial Chemotherapy Following Surgery in Treating Patients With Locally Advanced Bladder Cancer: a China,prospective, multicenter ,randomized phase III trial.
[VIRTUAL] Interim results of PEANUT: An open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC)
[VIRTUAL] Interim analysis of phase 2 randomized prospective study on neoadjuvant apalutamide/abiraterone acetate with prednisone and the feasibility of performing nerve-sparing radical prostatectomy in men with high-risk prostate cancer (NCT02949284)
[VIRTUAL] The Association of Cancer Specific Anxiety with Disease Aggressiveness in Men on Active Surveillance of Prostate Cancer
[VIRTUAL] Decision regret, adverse outcomes and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial